Bacillus coagulans Unique IS-2 and Reduced Ferritin Level

Doses used in studies

CFU/day: 2 billion (median 2 billion, IQR 2 billion–2 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
No adverse effects related to probiotic administration were observed, and the intervention was well tolerated by all patients.
from: Efficacy of Bacillus clausii UBBC-07 and Bacillus coagulans Unique IS-2 in Mitigating Pulm

1 of 1 paper

Efficacy of Bacillus clausii UBBC-07 and Bacillus coagulans Unique IS-2 in Mitigating Pulmonary Parameters in Patients With Moderate COVID-19 Symptoms.

2024-12-26
RCT · n = 56
Cureus 16(12)
- Mehdi Ali Mirza
- Rajiv Kumar Bandaru
- Ushasree T

PubMed: 39866999
DOI: 10.7759/cureus.76436

5 Insights on

Reduced Ferritin Level

High evidence

There was a significant reduction (p < 0.01) in serum ferritin levels for both Bacillus clausii UBBC-07 and Bacillus coagulans Unique IS-2 compared to the placebo group. The median reduction in serum ferritin levels on day seven was 350 μg/L (40.7%) in the Bacillus coagulans Unique IS-2 group...By day 14, the reductions were 630 μg/L (73.3%)

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 2 billion spores, twice daily for 14 days